A Prospective Randomized Controlled Trial of Direct Oral Anticoagulant Therapy with a Fully Magnetically Levitated LVAD: The DOT-HM3 Study

Purpose: Although the fully magnetically levitated HeartMate 3 (HM3) LVAD has demonstrated superiority in reducing pump thrombosis and stroke outcomes, the residual risk for non-surgical bleeding remains high. Whether direct oral anticoagulants that inhibit Factor Xa when used instead of Vitamin-K Antagonists (VKA) with the HM3 pump are safe, preserve clinical outcomes, and favorably influence bleeding complications remains unknown.

Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , Z. Tucanova, P. Ivak, S. Gregor, D.M. Kolesar, T. Marek, V. Melenovsky, J. Binova, Z. Dorazilova, M. Hegarova, M. Podolec, H. Riha, J. Connors, M.R. Mehra Source Type: research